Sun Pharma Advanced Research Company
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Sun Pharma Advanced Research Company (SPARC) is strategically transforming its R&D focus towards high-value therapeutic areas, such as Antibody-Drug Conjugates and Cell and Gene Therapies, which are expected to drive future revenue growth. Management's recent commentary highlights the successful sale of a Priority Review Voucher for $195 million, enhancing financial flexibility and supporting ongoing clinical advancements. Despite anticipated margin pressures due to regulatory scrutiny and compliance challenges, Vista's forecast indicates accelerating revenue growth beyond historical levels, underpinned by SPARC's innovative pipeline and strategic initiatives. The company's strong balance sheet further supports its investment case, aligning with Vista's fair valuation assessment. However, the upcoming leadership transition and the need to navigate complex regulatory landscapes present potential headwinds. Overall, SPARC's positioning within the expanding Pharma APIs and CRAMS industry, coupled with improving pricing power, suggests a constructive outlook. Key opportunities include the advancement of its clinical pipeline and the growing demand for contract manufacturing services, while watchpoints include regulatory challenges and reliance on imported APIs
Why We Like This Stock
- Strategic focus on high-value therapeutic areas is expected to drive future revenue growth
- Successful sale of a Priority Review Voucher enhances financial flexibility for clinical advancements
- Strong balance sheet supports ongoing investment in innovative pipeline and manufacturing capabilities
Things To Watch Out For
- Regulatory scrutiny and compliance issues may pressure margins in the near term
- Upcoming leadership transition introduces uncertainty regarding execution and organizational stability
- Reliance on imported APIs could pose challenges in meeting global demand
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 29 | 2 | 10 | 173 | 527 |
| Profit Before Tax (Cr.) | -389 | -345 | 1,564 | 12,920 | 49,245 |
| PBT Margin | -1345.0% | -19604.0% | 14940.2% | 7488.6% | 9351.5% |
| Net Profit (Cr.) | -390 | -346 | 1,564 | 9,690 | 36,934 |
| Earnings Per Share | -12.0 | -10.6 | 48.1 | 298.2 | 1136.4 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.